Back

An IGF2-anchored oncofetal state and relapse-associated transcriptomic module define systemic progression risk in early-onset colorectal cancer

Licitra-Rosa, E.; Mantini, G.; Persiani, F.; Ponterio, E.; Di Bella, S.; Lorenzon, L.; Scaglione, G.; Caimano, M.; D'Ugo, D.; Salvatore, L.; Calegari, M. A.; Zannoni, G.; Stassi, G.; De Maria, R.

2026-05-20 cancer biology
10.64898/2026.05.18.725955 bioRxiv
Show abstract

The epidemiological surge of early-onset colorectal cancer (EOCRC) is characterized by accelerated biological kinetics and disproportionately high rates of systemic relapse following curative-intent surgery. Because standard anatomical staging (TNM) lacks the resolution to accurately capture the intrinsic regenerative capacity of microscopic residual disease, we investigated the transcriptomic architecture of post-surgical failure in a strictly defined, curative-intent clinical pan-cohort. Unbiased transcriptomic profiling of the localized (M0) discovery sub-cohort identified IGF2 as the most significantly upregulated correlate of metachronous relapse. High-resolution isoform analysis revealed that this transcriptional output is predominantly driven by the embryonic (P4) and placental (P5) promoters. Systematic allele-specific expression (ASE) analysis supported widespread biallelic IGF2 expression consistent with relaxation of imprinting-domain control. This signal was not restricted to relapsing tumors, suggesting a recurrence-independent oncofetal baseline across the EOCRC spectrum. Because this foundational epigenetic unlocking is functionally insufficient on its own to execute systemic metastasis, we distilled the additional transcriptional plasticity required for dissemination into an internally derived and bootstrap-stabilized 5-gene recurrence-risk module Multivariable analysis across the combined pan-cohort supported an independent association between the high-risk module and systemic relapse (p < 0.001), capturing prognostic dimensions completely unresolved by classical pathological covariates and baseline staging. Ultimately, our findings reframe EOCRC aggressiveness as the product of a dual-hit architecture. This framework resolves the clinical paradox of widespread IGF2 LOI co-existing with heterogeneous outcomes, offering a biologically grounded basis for molecular risk stratification beyond anatomical boundaries.

Matching journals

The top 7 journals account for 50% of the predicted probability mass.

1
Cancer Discovery
61 papers in training set
Top 0.1%
12.0%
2
Nature Communications
4913 papers in training set
Top 20%
9.8%
3
Nature
575 papers in training set
Top 3%
9.8%
4
Molecular Cell
308 papers in training set
Top 2%
7.0%
5
Science
429 papers in training set
Top 6%
6.1%
6
Cell Reports
1338 papers in training set
Top 11%
4.7%
7
Developmental Cell
168 papers in training set
Top 4%
4.7%
50% of probability mass above
8
Nature Cancer
35 papers in training set
Top 0.2%
4.7%
9
Cancer Research
116 papers in training set
Top 1%
3.0%
10
Cell
370 papers in training set
Top 8%
2.7%
11
Nature Genetics
240 papers in training set
Top 3%
2.7%
12
Nature Cell Biology
99 papers in training set
Top 2%
2.3%
13
Cell Genomics
162 papers in training set
Top 3%
2.0%
14
Immunity
58 papers in training set
Top 2%
2.0%
15
Cell Reports Medicine
140 papers in training set
Top 3%
2.0%
16
Cancer Cell
38 papers in training set
Top 0.9%
1.8%
17
Journal of Clinical Investigation
164 papers in training set
Top 3%
1.6%
18
Nature Medicine
117 papers in training set
Top 3%
1.4%
19
eLife
5422 papers in training set
Top 46%
1.4%
20
Genome Medicine
154 papers in training set
Top 6%
1.3%
21
Journal of Experimental Medicine
106 papers in training set
Top 3%
1.2%
22
Proceedings of the National Academy of Sciences
2130 papers in training set
Top 40%
1.1%
23
Science Advances
1098 papers in training set
Top 25%
1.1%
24
Cell Stem Cell
57 papers in training set
Top 2%
0.9%
25
Nature Ecology & Evolution
113 papers in training set
Top 5%
0.7%
26
Oncogene
76 papers in training set
Top 2%
0.7%
27
Cell Systems
167 papers in training set
Top 13%
0.7%
28
The EMBO Journal
267 papers in training set
Top 7%
0.6%
29
Science Translational Medicine
111 papers in training set
Top 8%
0.6%
30
JCI Insight
241 papers in training set
Top 9%
0.6%